journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Hematology

journal
https://www.readbyqxmd.com/read/29330746/risk-stratified-therapy-for-children-with-flt3-itd-positive-acute-myeloid-leukemia-results-from-the-jplsg-aml-05-study
#1
Akira Shimada, Yuka Iijima-Yamashita, Akio Tawa, Daisuke Tomizawa, Miho Yamada, Shiba Norio, Tomoyuki Watanabe, Takashi Taga, Shotaro Iwamoto, Kiminori Terui, Hiroshi Moritake, Akitoshi Kinoshita, Hiroyuki Takahashi, Hideki Nakayama, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Akiko Moriya Saito, Nobutaka Kiyokawa, Keizo Horibe, Yusuke Hara, Kentaro Oki, Yasuhide Hayashi, Shiro Tanaka, Souichi Adachi
Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AMLFLT3-ITD) is associated with poor prognosis. We evaluated the results of the AML-05 study, in which all AMLFLT3-ITD patients were assigned to receive hematopoietic stem cell transplantation (HSCT) in the first remission (1CR). We also investigated the effects of additional genetic alterations on FLT3-ITD. The 5-year overall survival (OS) and event-free survival (EFS) rates among the 47 AMLFLT3-ITD patients were 42...
January 12, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29327325/circulating-level-of-th17-cells-is-associated-with-sensitivity-to-glucocorticoids-in-patients-with-immune-thrombocytopenia
#2
YiChan Zhang, TingTing Ma, Xuan Zhou, JunHao Chen, Juan Li
Glucocorticoids are a widely recognized first-line therapy for immune thrombocytopenia (ITP). However, some patients are unresponsive to glucocorticoid therapy for reasons that remain unclear. Accumulating evidence suggests that CD4+ T-cell abnormalities play a crucial role in the development of ITP. In the present study, we investigated peripheral blood CD4+ T cells, Th17-associated cytokines, and the mRNA expression level of Th17 transcription factor-RORγt-in patients with newly-diagnosed ITP before glucocorticoid therapy...
January 11, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29305770/deferasirox-for-the-treatment-of-iron-overload-after-allogeneic-hematopoietic-cell-transplantation-multicenter-phase-i-study-ksgct1302
#3
Takayoshi Tachibana, Junya Kanda, Shinichiro Machida, Takeshi Saito, Masatsugu Tanaka, Yuho Najima, Satoshi Koyama, Takuya Miyazaki, Eri Yamamoto, Masahiro Takeuchi, Satoshi Morita, Yoshinobu Kanda, Heiwa Kanamori, Shinichiro Okamoto
The aim of this study was to assess the safety and optimal dose of deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation (HCT). The primary endpoint was the maximum tolerated dose of deferasirox that was determined by the intrapatient dose escalation methods. A total of 16 patients with post-HCT iron overload were enrolled in the study. After excluding one case of early relapse, 15 remained evaluable. Their median age was 42 years (range 22-68). Median time from HCT to deferasirox administration was 9 months (range 6-84)...
January 5, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29299798/mild-renal-dysfunction-defined-by-creatinine-clearance-rate-has-limited-impact-on-clinical-outcomes-after-allogeneic-hematopoietic-stem-cell-transplantation
#4
Shuntaro Ikegawa, Ken-Ichi Matsuoka, Tomoko Inomata, Naoto Ikeda, Hiroyuki Sugiura, Taiga Kuroi, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Nobuharu Fujii, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto
Creatinine clearance rate (Ccr) is a more accurate indicator of renal function than serum creatinine. Data are sparse regarding the prognostic value of renal impairment calculated using Ccr in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis of 185 patients who underwent allo-HSCT. These patients were divided into two groups by Ccr (ml/min) before transplantation; one showed normal renal function (Ccr ≥ 60, n = 156) and the other showed mild renal dysfunction (30 ≤ Ccr < 60, n = 29), and transplant outcomes were compared between the groups...
January 4, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29290077/efficacy-and-safety-of-interferon-alpha-for-essential-thrombocythemia-during-pregnancy-two-cases-and-a-literature-review
#5
Kazuya Sakai, Akane Ueda, Masaaki Hasegawa, Yasunori Ueda
For pregnant women with essential thrombocythemia (ET), no standard approach for managing the platelet count has been established. We present the cases of two pregnant women with ET treated with interferon (IFN)-alpha. Each case showed a marked platelet decrease, from values within normal limits at the time of delivery, with no severe adverse events. To clarify the efficacy and safely of IFN alpha for ET during pregnancy, we performed a literature review. A total of 43 pregnant women with ET were ultimately identified from 12 articles and the present cases...
December 30, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29264741/rearrangement-of-vps13b-a-causative-gene-of-cohen-syndrome-in-a-case-of-runx1-runx1t1-leukemia-with-t-8-12-21
#6
Akihiro Abe, Yukiya Yamamoto, Akira Katsumi, Akinao Okamoto, Masutaka Tokuda, Yoko Inaguma, Kiyoko Yamamoto, Masamitsu Yanada, Tadaharu Kanie, Akihiro Tomita, Yoshiki Akatsuka, Masataka Okamoto, Toshiki Kameyama, Akila Mayeda, Nobuhiko Emi
Variant chromosomal translocations associated with t(8;21) are observed in 3-4% of acute myeloid leukemia (AML) cases with a RUNX1-RUNX1T1 fusion gene. However, the molecular events that occur in variants of t(8;21) are not well characterized. In the present study, we report genetic features of a variant three-way translocation of t(8;12;21)(q22;p11;q22) in a patient with AML. In this patient, leukemia cells lacked azurophilic granules, which does not correspond with the classic features of t(8;21). RNA-seq analysis revealed that TM7SF3 at 12p11 was fused to VPS13B at 8q22 and VPS13B to RUNX1, in addition to RUNX1-RUNX1T1...
December 20, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29260507/safety-and-efficacy-of-daratumumab-in-combination-with-bortezomib-and-dexamethasone-in-japanese-patients-with-relapsed-or-refractory-multiple-myeloma
#7
Shinsuke Iida, Tatsuo Ichinohe, Atsushi Shinagawa, Kenshi Suzuki, Naoki Takezako, Masayuki Aoki
Daratumumab in combination with bortezomib and dexamethasone (DVd) has demonstrated longer progression-free survival than combination of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). In this multicenter, open-label, phase-1 study, the safety, efficacy, and pharmacokinetics (PK) of DVd were evaluated in Japanese patients with RRMM. Eight patients with RRMM aged between 54 and 82 years were enrolled and treated with DVd regimen. Primary endpoints were tolerability and safety...
December 19, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29260506/new-immunotherapy-based-approach-in-allogeneic-hematopoietic-stem-cell-transplantation
#8
EDITORIAL
Yoshinobu Maeda
No abstract text is available yet for this article.
December 19, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29243031/prospective-randomization-of-post-remission-therapy-comparing-autologous-peripheral-blood-stem-cell-transplantation-versus-high-dose-cytarabine-consolidation-for-acute-myelogenous-leukemia-in-first-remission
#9
Toshihiro Miyamoto, Koji Nagafuji, Tomoaki Fujisaki, Naoyuki Uchida, Kosei Matsue, Hideho Henzan, Ryosuke Ogawa, Ken Takase, Takatoshi Aoki, Michihiro Hidaka, Takanori Teshima, Shuichi Taniguchi, Koichi Akashi, Mine Harada
We prospectively compared outcomes of autologous stem cell transplantation (ASCT) versus high-dose cytarabine (HiDAC) consolidation as post-remission therapy for favorable- and intermediate-risk acute myelogenous leukemia (AML) in first complete remission (CR1). Two-hundred-forty patients under 65 years with AML-M1, M2, M4, or M5 subtypes were enrolled. After induction, 153 patients did not undergo randomization, while the remaining 87 who achieved CR1 were prospectively randomized to HiDAC (n = 45) or ASCT arm (n = 42)...
December 14, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29234981/sarcopenia-after-induction-therapy-in-childhood-acute-lymphoblastic-leukemia-its-clinical-significance
#10
Daisuke Suzuki, Ryoji Kobayashi, Hirozumi Sano, Daiki Hori, Kunihiko Kobayashi
Muscle weakness is one of the most serious problems during chemotherapy for childhood hematological malignancies. It may be caused by long-term hospitalization, unfavorable physical conditions, and restricted activities. Although the concept of sarcopenia is becoming widely recognized, especially in geriatric medicine, there have been few reports about sarcopenia in pediatric patients with hematological malignancies. A total of 47 consecutive first-onset acute lymphoblastic leukemia (ALL) patients who underwent induction therapy between January 2011 and September 2016 were investigated...
December 12, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29234980/low-dose-interleukin-2-as-a-modulator-of-treg-homeostasis-after-hsct-current-understanding-and-future-perspectives
#11
REVIEW
Ken-Ichi Matsuoka
CD4+CD25+Foxp3+ Treg is a functionally distinct subset of mature T cells with broad suppressive activity and has been shown to play an important role in the establishment of immune tolerance after HSCT. Altered cytokine environment in post-HSCT lymphopenia with a relative functional deficiency of IL-2 could hamper the reconstitution of Treg, leading to refractory GVHD. Based on the theory of low-dose IL-2 in which Treg can be selectively stimulated through the high-affinity IL-2 receptor, clinical studies have been conducted and demonstrated that low-dose IL-2 administration can restore Treg homeostasis and promote the expansion of this subset on the polymorphic processes of Treg reconstitution after HSCT...
December 12, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29218495/systemic-epstein-barr-virus-positive-t-cell-lymphoproliferative-disorders-of-childhood-with-fulminant-leukocytosis-and-tumor-lysis-a-case-report-with-autopsy-findings
#12
Sachie Wada, Takayuki Suzuki, Koichi Kitazume, Akira Fujita, Seiichiro Shimizu
Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoproliferative disorders (T-LPD) of childhood is an extremely rare disease characterized by an aggressive clinical course and very poor prognosis. We report an adolescent male with systemic EBV-positive T-LPD of childhood after primary EBV infection, resulting in a fatal clinical course within 9 days, along with autopsy findings. A 19-year-old male without an immunocompromised status presented with an acute onset of high fever, and was hospitalized for persistent fever, vomiting and diarrhea on the 5th day from onset...
December 7, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29209948/iron-metabolism-and-related-diseases-an-overview
#13
EDITORIAL
Hideo Harigae
No abstract text is available yet for this article.
December 5, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29197980/correction-to-iron-and-infection
#14
Tomas Ganz
The author would like to correct the error in the "Abstract" section of original publication as given below.
December 2, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29196968/nk-cell-therapy-after-hematopoietic-stem-cell-transplantation-can-we-improve-anti-tumor-effect
#15
REVIEW
Catharina H M J Van Elssen, Stefan O Ciurea
After decades since the discovery of natural killer (NK) cells as potential effector cells fighting malignantly transformed and virally infected cells, little progress has been made in their clinical application. This yet unrealized therapeutic effect is presumably, at least in part, due to low numbers of functional NK cells that could be obtained from the peripheral blood relative to tumor burden. Our group hypothesized that a relatively small NK cell number to targeted malignant cells is the cause of a lack of clinical effect...
December 1, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29196967/modern-iron-replacement-therapy-clinical-and-pathophysiological-insights
#16
REVIEW
Domenico Girelli, Sara Ugolini, Fabiana Busti, Giacomo Marchi, Annalisa Castagna
Iron deficiency, with or without anemia, is extremely frequent worldwide, representing a major public health problem. Iron replacement therapy dates back to the seventeenth century, and has progressed relatively slowly until recently. Both oral and intravenous traditional iron formulations are known to be far from ideal, mainly because of tolerability and safety issues, respectively. At the beginning of this century, the discovery of hepcidin/ferroportin axis has represented a turning point in the knowledge of the pathophysiology of iron metabolism disorders, ushering a new era...
December 1, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29188583/infusions-of-epstein-barr-virus-specific-cytotoxic-t-lymphocytes-as-post-remission-therapy-in-high-risk-post-transplant-lymphoproliferative-disorder-patients-report-of-two-cases
#17
Nayoun Kim, Hyun-Jung Sohn, Joo Hyun Oh, Young-Woo Jeon, Hyun-Joo Lee, Hyun-Il Cho, Byung Ha Chung, Chul-Woo Yang, Tai-Gyu Kim, Seok-Goo Cho
Conventional therapeutic approaches to post-transplant lymphoproliferative disorder (PTLD) occurring after solid-organ transplantation have shown only limited success in achieving durable response. Key factors driving the pathogenesis of PTLD include Epstein-Barr virus (EBV) reactivation and impaired immune surveillance due to prolonged immune suppression. Thus, EBV-specific cytotoxic T lymphocytes (EBV-CTLs) have emerged as an alternative therapeutic approach for the treatment of EBV-associated PTLD by enhancing EBV-specific immunity...
November 29, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29188582/a-low-birth-weight-infant-with-no-malformations-delivered-by-a-primary-immune-thrombocytopenia-patient-treated-with-eltrombopag
#18
Naruko Suzuki, Junji Hiraga, Yumi Hariyama, Yusuke Takagi, Haruhiko Ohashi, Yasuyuki Kishigami, Hidenori Oguchi, Yoshitoyo Kagami
Primary immune thrombocytopenia (ITP) is defined by a low platelet count secondary to antibody-mediated platelet destruction or reductions in platelet production. Although eltrombopag is a thrombopoietin receptor agonist that increases platelet production in refractory or relapsed ITP, the influence on pregnancy is limited. We present the case of a pregnant 25-year-old ITP patient referred to our hospital with a history of two induced abortions. After eradication of Helicobacter pylori and with oral prednisolone at 8 mg/day, platelet count remained below 10,000/µl...
November 29, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29188581/marked-erythroblastosis-in-myelodysplastic-syndrome-induced-by-gastric-hemorrhaging
#19
LETTER
Sakiko Yoshimura, Wataru Munakata, Chiaki Ikeda, Hiromichi Matsushita
No abstract text is available yet for this article.
November 29, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29188580/10-year-complete-remission-in-a-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-patient-using-imatinib-without-high-intensity-chemotherapy-or-allogeneic-stem-cell-transplantation
#20
Katsumichi Fujimaki, Yukako Hattori, Hideaki Nakajima
The outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) has improved with the use of tyrosine kinase inhibitors, such as imatinib and dasatinib. We report a 63-year-old woman with Ph-ALL who maintained complete remission for 10 years using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation. She underwent induction therapy with imatinib plus prednisolone and achieved complete remission by day 53. Imatinib was continued until 103 months, when it was stopped in response to renal dysfunction; however, the patient continued to exhibit molecular remission at 120 months...
November 29, 2017: International Journal of Hematology
journal
journal
30826
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"